It is not clear whether TOT was better due to dose reductions or whether TOT was worse due to dose maintenance, but a study that investigated the effect of dose adjustment on survival outcomes in patients with EGFR‐mutated NSCLC reported that patients who received dose reductions experienced higher ORRs.19 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.